Xeroshield has now completed its proof of market study for a new preventative technology for tackling ticks and Lyme disease and submitted this to the UK Technology Strategy Board.
We are extremely grateful to all organisations and individuals that contributed to the successful completion of the study. Anyone interested in reading a summary of the main conclusions from the study can access a summary report by clicking on the following web-link:
Xeroshield Summary Report – Ticks and Lyme Disease Study 2012
Xeroshield is now actively seeking support and funding to be able to progress its technology to the next stage of development and would welcome contact from anyone interested in discussing this in further detail:
Contact: Bruce Alexander, Managing Director
Xeroshield Ltd
Wallace Building
Roslin BioCentre
Roslin
Midlothian
EH25 9PP
E-mail: bruce.alexander@xeroshield.com
Tel: 0131 200 6377
Reg. No. SC286434
Thank you for your interest and support.